Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin PK/PD in Renal Impairment
NCT02191228Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve at steady state, Maximum concentration at steady state and 2 more. Started Apr 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02191228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191228.